Jagsonpal Pharmaceuticals Ltd Q2 FY26 – ₹745 Mn Sales, ₹126 Mn PAT, and an Acquisition-Fueled Rebirth That’s Part Mid-Life Crisis, Part Masterstroke
1. At a Glance
Jagsonpal Pharmaceuticals (JPL) is that mid-sized pharma player who just got a second wind — like a Bollywood actor landing a Netflix comeback. With a market cap of ₹1,512 crore and a stock price of ₹226, JPL is no longer the sleepy formulation maker it once was. It’s now scripting its turnaround arc, powered by acquisitions, new product launches, and a CFO carousel spinning faster than an ECG monitor in an ICU.
In Q2 FY26, Jagsonpal posted sales of ₹745 million (₹74.5 crore) and PAT of ₹126 million (₹12.6 crore). The year-on-year revenue stayed flat, but PAT grew ~10%, driven by margin expansion and a bit of other-income magic. H1 FY26 consolidated revenue stood at ₹1,501 million, up 10.2% YoY, while PAT jumped 39.2%.
Return ratios remain heroic for a small-cap: ROCE 23%, ROE 18.6%, and Debt-to-Equity 0.03 — that’s near-zero leverage, basically running on pure adrenaline and retained earnings. Yet, with a P/E of 34.6, the market already prices it like a niche wellness brand, not a mid-tier generic maker. Still, for a company that once sold gynaecology tablets and antibiotics quietly, it’s now got investors’ full attention — and a little sass in its balance sheet.
2. Introduction
Jagsonpal Pharmaceuticals began in 1978 — the disco era — and somehow survived everything from license raj to the GST age. This Gurgaon-based player has finally stepped out of the shadows, largely thanks to its pivot into women’s health and dermatology.
JPL was long considered a sleepy small-cap, with modest operations and a “loan licensing” model (a polite way to say, “we outsource everything except marketing”). But under the new Infinity Holdings regime, the company’s ambition got a protein shake. They’re now snatching brands, expanding into skincare, and launching formulations faster than a government scheme launches acronyms.
Its top 5 brands contribute nearly half its revenue — a risky but focused bet. Their formulations cater to gynecology, orthopedics, dermatology, and pediatrics, while exports remain tiny at 2%. This is an India-first company in the truest sense: made for the Indian doctor, prescribed to the Indian patient, and priced for the Indian chemist’s shelf.
The new energy post-2024 acquisitions shows. FY25 revenue grew nearly 29%, profit surged 63%, and management has started actually attending concalls like they mean it. There’s a new COO, a new CFO, and a new swagger — not bad for a company that once depended on one injectable to stay relevant.
3. Business Model – WTF Do They Even Do?
Think of JPL as the marketing brain of a pharma body it doesn’t own. The company doesn’t manufacture its own products — it outsources the production through loan licensing arrangements. In short, other companies make the drugs, JPL sells them — the pharma version of Uber.
Its model revolves around branding, distribution, and medical reach, not heavy capex or R&D. That’s why it can run an impressive 6.07 current ratio — light on assets, high on receivables, low on debt.
The business pivots around:
Gynaecology & Orthopaedics (Core segments) – The “female-focused” and “joint-care” divisions that bring in the majority of sales.
Dermatology and Pediatrics (New growth) – Post its ₹93 crore acquisition from Yash Pharma (May 2024), JPL added high-margin skincare and pediatric brands like Eukroma, Itratop, Ventiphylline-PD, and Tinilox.
OTC and Nutraceuticals – With brands like Lycored Plus and MemUp, they’ve tapped the modern “wellness” trend.
Top brands like Indocap, Maintane, Divatrone, Endoreg, and Equirex dominate prescriptions in their respective molecules. In FY24, about 47% of revenue came from top 5 brands and 67% from top 7 — it’s basically a brand oligarchy inside one company.
Their approach: outsource manufacturing, invest in doctors, expand via acquisitions — a “capex-free, cash-flow-friendly” model that’s become popular among nimble pharma firms.
4. Financials Overview
Source table
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
₹74.5 Cr
₹74.7 Cr
₹76 Cr
-0.3%
-2.0%
EBITDA
₹16 Cr
₹16 Cr
₹14 Cr
0.0%
14.3%
PAT
₹12.6 Cr
₹11 Cr
₹11 Cr
9.7%
14.5%
EPS (₹)
1.89
1.73
1.62
9.2%
16.7%
Flat revenues, but stable EBITDA and rising PAT — that’s the classic “small-cap efficiency story.” Jagsonpal squeezed profits despite stagnant top line, largely due to disciplined cost control and strong product mix.
At ₹1.89 quarterly EPS, annualized EPS is around ₹7.5, giving it a forward P/E near 30x. It’s not cheap, but neither is growth driven by newly acquired brands and rising margin visibility.
5. Valuation Discussion – Fair Value Range Only
Let’s pop open the spreadsheet like it’s paracetamol time.
a) P/E Method: TTM EPS = ₹9.32 Industry P/E = 33 Applying a conservative 30–36x multiple gives a fair value range of ₹280–₹335 per share.
b) EV/EBITDA Method: EV = ₹1,362 Cr EBITDA (FY25) = ₹66 Cr EV/EBITDA
